Recombinant Bispecific Monoclonal Antibodies Prepared by the Dock-and-Lock Strategy for Pretargeted Radioimmunotherapy

Seminars in Nuclear Medicine

Volumn 40, Issue 3, 2010, Pages 190-203

  Sharkey, Robert M ^a   Rossi, Edmund A ^b   McBride, William J ^c   Chang, Chien Hsing ^c   Goldenberg, David M ^a  

^a CENTER FOR MOLECULAR MEDICINE AND IMMUNOLOGY   (United States)

^b IBC Pharmaceuticals Inc   (United States)

^c IMMUNOMEDICS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; BISPECIFIC ANTIBODY; CARCINOEMBRYONIC ANTIGEN; EDETIC ACID; FLUORINE 18; FLUORODEOXYGLUCOSE F 18; GALLIUM 68; HAPTEN; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G; IMP 288; INDIUM 111; INOSINE PHOSPHATE; IODINE 124; IODINE 131; LUTETIUM 177; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY TF2; PENTETATE INDIUM IN 111; PENTETIC ACID; PEPTIDE; RADIOISOTOPE; RECOMBINANT ANTIBODY; RHENIUM 188; STREPTAVIDIN; TECHNETIUM 99M; TUMOR ANTIGEN; UNCLASSIFIED DRUG; YTTRIUM 90;

ANTIBODY ENGINEERING; ANTIBODY STRUCTURE; BLOOD TOXICITY; CLINICAL TRIAL; COLORECTAL CANCER; DOCK AND LOCK METHOD; DOSE RESPONSE; DRUG BINDING; DRUG CLEARANCE; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; HUMAN; ISOTOPE LABELING; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; RADIATION DOSE; RADIOIMMUNOTHERAPY; RADIOSENSITIVITY; REVIEW; SCINTISCANNING;

ANTIBODIES, MONOCLONAL; DRUG DELIVERY SYSTEMS; HUMANS; ISOTOPE LABELING; NEOPLASMS; RADIOIMMUNOTHERAPY; RADIOPHARMACEUTICALS; RECOMBINANT PROTEINS;

EID: 77949883007     PISSN: 00012998     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.semnuclmed.2009.12.002     Document Type: Review

References (116)

1. Pressman D., and Korngold L. The in vivo localization of anti-Wagner-osteogenic-sarcoma antibodies. Cancer 6 (1953) 619-623
2. 131. Cancer Res 16 (1956) 761-773
3. Bale W.F., and Spar I.L. Studies directed toward the use of antibodies as carriers of radioactivity for therapy. Adv Biol Med Phys 5 (1957) 285-356
4. McCardle R.J., Harper P.V., Spar I.L., et al. Studies with iodine-131-labeled antibody to human fibrinogen for diagnosis and therapy of tumors. J Nucl Med 7 (1966) 837-847
5. Goldenberg D.M., DeLand F., Kim E., et al. Use of radiolabeled antibodies to carcinoembryonic antigen for the detection and localization of diverse cancers by external photo scanning. N Engl J Med 298 (1978) 1384-1386
6. Goldenberg D.M., Gaffar S.A., Bennett S.J., et al. Experimental radioimmunotherapy of a xenografted human colonic tumor (GW-39) producing carcinoembryonic antigen. Cancer Res 41 (1981) 4354-4360
7. Ettinger D.S., Dragon L.H., Klein J., et al. Isotopic immunoglobulin in an integrated multimodal treatment program for a primary liver cancer: A case report. Cancer Treat Rep 63 (1979) 131-134
8. Order S.E., Klein J.L., Ettinger D., et al. Phase I-II study of radiolabeled antibody integrated in the treatment of primary hepatic malignancies. Int J Radiat Oncol Biol Phys 6 (1980) 703-710
9. Order S.E., Klein J.L., and Leichner P.K. Antiferritin IgG antibody for isotopic cancer therapy. Oncology 38 (1981) 154-160
10. Carrasquillo J.A., Krohn K.A., Beaumier P., et al. Diagnosis of and therapy for solid tumors with radiolabeled antibodies and immune fragments. Cancer Treat Rep 68 (1984) 317-328
11. Sharkey R.M., and Goldenberg D.M. Perspective on cancer therapy with radiolabeled monoclonal antibodies. J Nucl Med 46 (2005) 115S-127S
12. DeNardo S.J., DeNardo G.L., O'Grady L.F., et al. Treatment of a patient with B cell lymphoma by I-131 LYM-1 monoclonal antibodies. Int J Biol Markers 2 (1987) 49-53
13. 131I Lym-1 monoclonal antibodies. Int J Cancer Suppl 3 (1988) 96-101
14. Press O.W., Eary J.F., Badger C.C., et al. Treatment of refractory non-Hodgkin's lymphoma with radiolabeled MB-1 (anti-CD37) antibody. J Clin Oncol 7 (1989) 1027-1038
15. Scheinberg DA, Lovett D, Divgi CR, et al: A phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: Specific bone marrow targeting and internalization of radionuclide. J Clin Oncol 9:478-490
16. Kaminski M.S., Fig L.M., Zasadny K.R., et al. Imaging, dosimetry, and radioimmunotherapy with iodine 131-labeled anti-CD37 antibody in B-cell lymphoma. J Clin Oncol 10 (1992) 1696-1711
17. Emmanouilides C. Radioimmunotherapy for non-Hodgkin lymphoma: Historical perspective and current status. J Clin Exp Hematop 47 (2007) 43-60
18. Schaefer-Cutillo J., and Friedberg J.W. Non-myeloablative radioimmunotherapy for non-Hodgkin's lymphoma. Semin Hematol 45 (2008) 110-117
19. Buchegger F., Press O.W., Delaloye A.B., et al. Radiolabeled and native antibodies and the prospect of cure of follicular lymphoma. Oncologist 13 (2008) 657-667
20. Koral K.F., Dewaraja Y., Clarke L.A., et al. Tumor-absorbed-dose estimates versus response in tositumomab therapy of previously untreated patients with follicular non-Hodgkin's lymphoma: Preliminary report. Cancer Biother Radiopharm 15 (2000) 347-355
21. 131I-anti-B1 antibody: Assessment of tumor dose-response. J Nucl Med 44 (2003) 260-268
22. 90Y-Epratuzumab): Do tumor targeting and dosimetry predict therapeutic response?. J Nucl Med 44 (2003) 2000-2018
23. 131I-labeled murine monoclonal antibody to carcinoembryonic antigen. Cancer Res 47 (1987) 5672-5677
24. Boerman O.C., Sharkey R.M., Blumenthal R.D., et al. The presence of a concomitant bulky tumor can decrease the uptake and therapeutic efficacy of radiolabeled antibodies in small tumors. Int J Cancer 51 (1992) 470-475
25. Sharkey R.M., and Goldenberg D.M. Use of antibodies and immunoconjugates for the therapy of more accessible cancers. Adv Drug Deliv Rev 60 (2008) 1407-1420
26. 131I-labetuzumab after salvage resection of colorectal liver metastases: Comparison of outcome to a contemporaneous control group. Ann Surg Oncol 14 (2007) 2577-2590
27. Shibata S., Raubitschek A., Leong L., et al. A phase I study of a combination of yttrium-90-labeled anti-carcinoembryonic antigen (CEA) antibody and gemcitabine in patients with CEA-producing advanced malignancies. Clin Cancer Res 15 (2009) 2935-2941
28. Pennington K., Guarino M.J., Serafini A.N., et al. Multicenter study of radiosensitizing gemcitabine combined with fractionated radioimmunotherapy for repeated treatment cycles in advanced pancreatic cancer. J Clin Oncol 27 (2009) 15s abstract 4620
29. 90Yttrium-labeled monoclonal antibody CC49: A phase I trial. Clin Cancer Res 6 (2000) 3095-3102
30. 90Y-labeled humanized anti-CEA monoclonal antibody with doxorubicin and peripheral blood stem cell rescue in advanced medullary thyroid cancer. J Nucl Med 46 (2005) 620-633
31. Richman C.M., Denardo S.J., O'Donnell R.T., et al. High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170, linked to indium-111/yttrium-90 via a cathepsin cleavable linker with cyclosporine to prevent human anti-mouse antibody. Clin Cancer Res 11 (2005) 5920-5927
32. Sharkey R.M., Motta-Hennessy C., Pawlyk D., et al. Biodistribution and radiation dose estimates for yttrium- and iodine-labeled monoclonal antibody IgG and fragments in nude mice bearing human colonic tumor xenografts. Cancer Res 50 (1990) 2330-2336
33. Mueller B.M., Reisfeld R.A., and Gillies S.D. Serum half-life and tumor localization of a chimeric antibody deleted of the CH2 domain and directed against the disialoganglioside GD2. Proc Natl Acad Sci USA 87 (1990) 5702-5705
34. Colcher D., Goel A., Pavlinkova G., et al. Effects of genetic engineering on the pharmacokinetics of antibodies. Q J Nucl Med 43 (1999) 132-139
35. Batra S.K., Jain M., Wittel U.A., et al. Pharmacokinetics and biodistribution of genetically engineered antibodies. Curr Opin Biotechnol 13 (2002) 603-608
36. Kenanova V., and Wu A.M. Tailoring antibodies for radionuclide delivery. Expert Opin Drug Deliv 3 (2006) 53-70
37. Begent R.H., Green A.J., Bagshawe K.D., et al. Liposomally entrapped second antibody improves tumour imaging with radiolabeled (first) antitumour antibody. Lancet 320 (1982) 739-742
38. Sharkey R.M., Primus F.J., and Goldenberg D.M. Second antibody clearance of radiolabeled antibody in cancer radioimmunodetection. Proc Natl Acad Sci USA 81 (1984) 2843-2846
39. Mårtensson L., Nilsson R., Ohlsson T., et al. Reduced myelotoxicity with sustained tumor concentration of radioimmunoconjugates in rats after extracorporeal depletion. J Nucl Med 48 (2007) 269-276
40. Behr T.M., Memtsoudis S., Sharkey R.M., et al. Experimental studies on the role of antibody fragments in cancer radio-immunotherapy: Influence of radiation dose and dose rate on toxicity and anti-tumor efficacy. Int J Cancer 77 (1998) 787-795
41. 90Y-labeled CO17-1A Fab′ fragments in a human colonic cancer model. Cancer Res 59 (1999) 2635-2643
42. O'Donoghue J. Relevance of external beam dose-response relationships to kidney toxicity associated with radionuclide therapy. Cancer Biother Radiopharm 19 (2004) 378-387
43. 90Y-DOTATOC: Relevance of kidney volume and dose rate in finding a dose-effect relationship. J Nucl Med 46 suppl 1 (2005) 99S-106S
44. van Essen M., Krenning E.P., Kam B.L., et al. Peptide-receptor radionuclide therapy for endocrine tumors. Nat Rev Endocrinol 5 (2009) 382-393
45. Behr T.M., Sharkey R.M., Sgouros G., et al. Overcoming the nephrotoxicity of radiometal-labeled immunoconjugates: Improved cancer therapy administered to a nude mouse model in relation to the internal radiation dosimetry. Cancer 80 (1997) 2591-2610
46. Lambert B., Cybulla M., Weiner S.M., et al. Renal toxicity after radionuclide therapy. Radiat Res 161 (2004) 607-611
47. 111In-octreotide in mice and rats. J Nucl Med 47 (2006) 528-533
48. Vegt E., Wetzels J.F., Russel F.G., et al. Renal uptake of radiolabeled octreotide in human subjects is efficiently inhibited by succinylated gelatin. J Nucl Med 47 (2006) 432-436
49. 3]octreotate. Eur J Nucl Med Mol Imaging 34 (2007) 763-771
50. Vegt E, Eek A, Oyen WJ, et al: Albumin-derived peptides efficiently reduce renal uptake of radiolabelled peptides. Eur J Nucl Med Mol Imaging (in press)
51. 3-octreotate. J Nucl Med 46 suppl 1 (2005) 83S-91S
52. Cremonesi M., Ferrari M., Bodei L., et al. Dosimetry in peptide radionuclide receptor therapy: A review. J Nucl Med 47 (2006) 1467-1475
53. Peterson J.J., and Meares C.F. Enzymatic cleavage of peptide-linked radiolabels from immunoconjugates. Bioconjug Chem 10 (1999) 553-557
54. Reardan D.T., Meares C.F., Goodwin D.A., et al. Antibodies against metal chelates. Nature 316 (1985) 265-268
55. Stickney D.R., Anderson L.D., Slater J.B., et al. Bifunctional antibody: A binary radiopharmaceutical delivery system for imaging colorectal carcinoma. Cancer Res 51 (1991) 6650-6655
56. 111In-C110. Int J Rad Appl Instrum B 18 (1991) 705-710
57. Collier B.D., Abdel-Nabi H., Doerr R.J., et al. Immunoscintigraphy performed with In-111-labeled CYT-103 in the management of colorectal cancer: Comparison with CT. Radiology 185 (1992) 179-186
58. Le Doussal J.M., Martin M., Gautherot E., et al. In vitro and in vivo targeting of radiolabeled monovalent and divalent haptens with dual specificity monoclonal antibody conjugates: Enhanced divalent hapten affinity for cell-bound antibody conjugate. J Nucl Med 30 (1989) 1358-1366
59. Goodwin D.A., Meares C.F., McTigue M., et al. Pretargeted immunoscintigraphy: Effect of hapten valency on murine tumor uptake. J Nucl Med 33 (1992) 2006-2013
60. Boerman O.C., Kranenborg M.H., Oosterwijk E., et al. Pretargeting of renal cell carcinoma: Improved tumor targeting with a bivalent chelate. Cancer Res 59 (1999) 4400-4405
61. Goldenberg D.M., Sharkey R.M., Paganelli G., et al. Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy. J Clin Oncol 24 (2006) 823-834
62. Le Doussal J.M., Gruaz-Guyon A., Martin M., et al. Targeting of indium 111-labeled bivalent hapten to human melanoma mediated by bispecific monoclonal antibody conjugates: Imaging of tumors hosted in nude mice. Cancer Res 50 (1990) 3445-3452
63. Le Doussal J.M., Barbet J., and Delaage M. Bispecific-antibody-mediated targeting of radiolabeled bivalent haptens: Theoretical, experimental and clinical results. Int J Cancer Suppl 7 (1992) 58-62
64. Gautherot E., Bouhou J., Le Doussal J.M., et al. Therapy for colon carcinoma xenografts with bispecific antibody-targeted, iodine-131-labeled bivalent hapten. Cancer 80 suppl 12 (1997) 2618-2623
65. Gautherot E., Le Doussal J.M., Bouhou J., et al. Delivery of therapeutic doses of radioiodine using bispecific antibody-targeted bivalent haptens. J Nucl Med 39 (1998) 1937-1943
66. 2 and pretargeted bivalent hapten and evaluation of repeated injections. Clin Cancer Res 5 (1999) 3183s-3189s
67. 131I-labeled bivalent hapten. J Nucl Med 41 (2000) 480-487
68. 131I-labeled bivalent hapten in a phase I optimization clinical trial. J Nucl Med 47 (2006) 247-255
69. Chatal J.F., Campion L., Kraeber-Bodéré F., et al. Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy: A collaborative study with the French Endocrine Tumor Group. J Clin Oncol 24 (2006) 1705-1711
70. Axworthy D.B., Reno J.M., Hylarides M.D., et al. Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity. Proc Natl Acad Sci USA 97 (2000) 1802-1807
71. Sharkey R.M., Karacay H., Griffiths G.L., et al. Development of a streptavidin-anti-carcinoembryonic antigen antibody, radiolabeled biotin pretargeting method for radioimmunotherapy of colorectal cancer. Studies in a human colon cancer xenograft model. Bioconjug Chem 8 (1997) 595-604
72. 188Re-labeled peptide. Bioconjug Chem 11 (2000) 842-854
73. Karacay H., Sharkey R.M., McBride W.J., et al. Pretargeting for cancer radioimmunotherapy with bispecific antibodies: Role of the bispecific antibody's valency for the tumor target antigen. Bioconjug Chem 13 (2002) 1054-1070
74. Janevik-Ivanovska E., Gautherot E., Hillairet de Boisferon M., et al. Bivalent hapten-bearing peptides designed for iodine-131 pretargeted radioimmunotherapy. Bioconjug Chem 8 (1997) 526-533
75. Morel A., Darmon M., and Delaage M. Recognition of imidazole and histamine derivatives by monoclonal antibodies. Mol Immunol 27 (1990) 995-1000
76. Sharkey R.M., McBride W.J., Karacay H., et al. A universal pretargeting system for cancer detection and therapy using bispecific antibody. Cancer Res 63 (2003) 354-363
77. 68Ga-radiolabeled bivalent hapten-peptide-chelate conjugates. J Nucl Med 45 (2004) 30-39
78. Gruaz-Guyon A., Janevik-Ivanovska E., Raguin O., et al. Radiolabeled bivalent haptens for tumor immunodetection and radioimmunotherapy. Q J Nucl Med 45 (2001) 201-206
79. Morandeau L., Benoist E., Loussouarn A., et al. Synthesis of new bivalent peptides for applications in the Affinity Enhancement System. Bioconjug Chem 16 (2005) 184-193
80. 124I-labeled hapten-peptide. J Nucl Med 47 (2006) 1678-1688
81. 18F radiolabeling for PET. J Nucl Med 50 (2009) 991-998
82. Sharkey R.M., Karacay H., Chang C.H., et al. Improved therapy of non-Hodgkin's lymphoma xenografts using radionuclides pretargeted with a new anti-CD20 bispecific antibody. Leukemia 19 (2005) 1064-1069
83. Sharkey R.M., Cardillo T.M., Rossi E.A., et al. Signal amplification in molecular imaging by pretargeting a multivalent, bispecific antibody. Nat Med 11 (2005) 1250-1255
84. Karacay H., Brard P.Y., Sharkey R.M., et al. Therapeutic advantage of pretargeted radioimmunotherapy using a recombinant bispecific antibody in a human colon cancer xenograft. Clin Cancer Res 11 (2005) 7879-7885
85. Sharkey R.M., Karacay H., McBride W.J., et al. Bispecific antibody pretargeting of radionuclides for immuno-single-photon emission computed tomography and immuno-positron emission tomography molecular imaging: An update. Clin Cancer Res 13 (2007) 5577s-5585s
86. Sharkey R.M., Karacay H., Litwin S., et al. Improved therapeutic results by pretargeted radioimmunotherapy of non-Hodgkin's lymphoma with a new recombinant, trivalent, anti-CD20, bispecific antibody. Cancer Res 68 (2008) 5282-5290
87. Sharkey R.M., Karacay H., Vallabhajosula S., et al. Metastatic human colonic carcinoma: Molecular imaging with pretargeted SPECT and PET in a mouse model. Radiology 246 (2008) 497-507
88. Gold D.V., Goldenberg D.M., Karacay H., et al. A novel bispecific, trivalent antibody construct for targeting pancreatic carcinoma. Cancer Res 68 (2008) 4819-4826
89. Sharkey R.M., Karacay H., Johnson C.R., et al. Pretargeted versus directly targeted radioimmunotherapy combined with anti-CD20 antibody consolidation therapy of non-Hodgkin lymphoma. J Nucl Med 50 (2009) 444-453
90. 90Y IMP-288 alone and combined with gemcitabine. J Nucl Med 50 (2009) 2008-2016
91. Sharkey R.M., and Goldenberg D.M. Novel radioimmunopharmaceuticals for cancer imaging and therapy. Curr Opin Investig Drugs 9 (2008) 1302-1316
92. Rossi E.A., Sharkey R.M., McBride W., et al. Development of new multivalent-bispecific agents for pretargeting tumor localization and therapy. Clin Cancer Res 9 (2003) 3886S-3896S
93. Rossi E.A., Chang C.H., Losman M.J., et al. Pretargeting of carcinoembryonic antigen-expressing cancers with a trivalent bispecific fusion protein produced in myeloma cells. Clin Cancer Res 11 (2005) 7122s-7129s
94. Wong W., and Scott J.D. AKAP signalling complexes: Focal points in space and time. Nat Rev Mol Cell Biol 5 (2004) 959-970
95. Baillie G.S., Scott J.D., and Houslay M.D. Compartmentalisation of phosphodiesterases and protein kinase A: Opposites attract. FEBS Lett 579 (2005) 3264-3270
96. Rossi E.A., Goldenberg D.M., Cardillo T.M., et al. Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting. Proc Natl Acad Sci USA 103 (2006) 6841-6846
97. Chang C.H., Rossi E.A., and Goldenberg D.M. The dock and lock method: A novel platform technology for building multivalent, multifunctional structures of defined composition with retained bioactivity. Clin Cancer Res 13 (2007) 5586s-5591s
98. Rossi E.A., Goldenberg D.M., Cardillo T.M., et al. Novel designs of multivalent anti-CD20 humanized antibodies as improved lymphoma therapeutics. Cancer Res 68 (2008) 8384-8392
99. Goldenberg D.M., Rossi E.A., Sharkey R.M., et al. Multifunctional antibodies by the Dock-and-Lock method for improved cancer imaging and therapy by pretargeting. J Nucl Med 49 (2008) 158-163
100. Rossi E.A., Goldenberg D.M., Cardillo T.M., et al. Hexavalent bispecific antibodies represent a new class of anticancer therapeutics: 1. Properties of anti-CD20/CD22 antibodies in lymphoma. Blood 113 (2009) 6161-6171
101. Rossi E.A., Goldenberg D.M., Cardillo T.M., et al. CD20-targeted tetrameric interferon-alpha, a novel and potent immunocytokine for the therapy of B-cell lymphomas. Blood 114 (2009) 3864-3871
102. Chang C.H., Rossi E.A., Cardillo T.M., et al. A new method to produce monoPEGylated dimeric cytokines shown with human interferon-alpha2b. Bioconjug Chem (2009)
103. Sharkey R.M., Juweid M., Shevitz J., et al. Evaluation of a complementarity-determining region-grafted (humanized) anti-carcinoembryonic antigen monoclonal antibody in preclinical and clinical studies. Cancer Res 55 (1995) 5935s-5945s
104. Hajjar G., Sharkey R.M., Burton J., et al. Phase I radioimmunotherapy trial with iodine-131-labeled humanized MN-14 anti-carcinoembryonic antigen monoclonal antibody in patients with metastatic gastrointestinal and colorectal cancer. Clin Colorectal Cancer 2 (2002) 31-42
105. Sharkey R.M., Karacay H., Richel H., et al. Optimizing bispecific antibody pretargeting for use in radioimmunotherapy. Clin Cancer Res 9 (2003) 3897S-3913S
106. 90Y-DOTA-biotin with pretargeted NR-LU-10/streptavidin. Cancer Biother Radiopharm 14 (1999) 381-395
107. Shen S., Foreo A., LoBuglio A.F., et al. Patient-specific dosimetry of pretargeted radioimmunotherapy using CC49 fusion protein in patients with gastrointestinal malignancies. J Nucl Med 46 (2005) 642-651
108. Press O.W., Corcoran M., Subbiah K., et al. A comparative evaluation of conventional and pretargeted radioimmunotherapy of CD20-expressing lymphoma xenografts. Blood 98 (2001) 2535-2543
109. - expressing human lymphoma xenografts. J Nucl Med 44 (2003) 437-445
110. Pagel J.M., Matthews D.C., Kenoyer A., et al. Pretargeted radioimmunotherapy using anti-CD45 monoclonal antibodies to deliver radiation to murine hematolymphoid tissues and human myeloid leukemia. Cancer Res 69 (2009) 185-192
111. 131I anti-CD45 radioimmunotherapy effectively targets and treats T-cell non-Hodgkin lymphoma. Blood 113 (2009) 5905-5910
112. 90Y-DOTA-biotin. J Nucl Med 41 (2000) 131-140
113. Knox S.J., Goris M.L., Tempero M., et al. Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer. Clin Cancer Res 6 (2000) 406-414
114. Wessels B.W., Konijnenberg M.W., Dale R.G., et al. MIRD pamphlet No. 20: The effect of model assumptions on kidney dosimetry and response: Implications for radionuclide therapy. J Nucl Med 49 (2008) 1884-1899
115. Kraeber-Bodéré F., Saï-Maurel C., Campion L., et al. Enhanced antitumor activity of combined pretargeted radioimmunotherapy and paclitaxel in medullary thyroid cancer xenograft. Mol Cancer Ther 1 (2002) 267-274
116. Graves S.S., Dearstyne E., Lin Y., et al. Combination therapy with pretarget CC49 radioimmunotherapy and gemcitabine prolongs tumor doubling time in a murine xenograft model of colon cancer more effectively than either monotherapy. Clin Cancer Res 9 (2003) 3712-3721